Table 2.

Short-term changes in BASDAI and BASFI in biologic-naïve patients

Measure	Patient group	SEC	CER P	ETN	ADA	INF	GOL
Change in BASDAI	Respondersa	−4.60	−5.57	−4.47	−4.56	−7.94	−5.32
	Nonresponders	−1.01	−1.28	−1.02	−0.81	−1.82	−1.37
Change in BASFI	Responders	−3.75	−3.59	−3.44	−3.15	−3.96	−4.07
	Nonresponders	−1.17	−0.89	−0.85	−0.78	−0.98	−0.71

Notes: Bayesian fixed effects network meta-analysis.²²

^aResponders are those who showed BASDAI 50 response. Change in BASDAI data for biologic-naïve patients was not available for SEC and CER P and was assumed to be equivalent to the average of other biologics in the NMA. Change in BASFI data for biologic-naïve patients for CER P was not available and was assumed to be equivalent to the average of other biologics in the NMA (excluding SEC).

Abbreviations: ADA, adalimumab; AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; NMA, network meta-analysis; SEC, secukinumab.